TABLE 2.
Main pharmacokinetic and pharmacodynamic variables for MFXa
| Group MFX+RIF (n = 30) |
Group MFX (n = 20) |
||||
|---|---|---|---|---|---|
| Variable name (unit) | Arithmetic Mean (SD) |
Geometric Mean (SDb) | Arithmetic Mean (SD) |
Geometric Mean (SDb) | GMR (90% CI) |
| AUC0-24h (mg*h*L−1) | 17.5 (5.45) | 16.8 (1.34) | 28.5 (7.30) | 27.6 (1.29) | 0.61 (0.53–0.70) |
| Cmax (mg/L) | 2.16 (0.67) | 2.06 (1.37) | 2.62 (0.69) | 2.54 (1.30) | 0.81 (0.70–0.94) |
| Tmaxc (h) | 2.00 (1.03–2.89) | 2.02 (1.32–4.06) | |||
| MICd, n% | 17 (55) | 18 (90) | |||
| MICd (mg/L), n% | |||||
| 0.125 | 12 (39) | 9 (45) | |||
| 0.25 | 3 (10) | 9 (45) | |||
| 0.5 | 2 (6) | 0 (0) | |||
| AUC0-24h/MICc (h) | 117 (74.1–145) | 156 (100–214) | |||
| AUC0-24h/MIC > 100d, n% | 11 (65) | 14 (78) | |||
a
Based on a dose of 400 mg moxifloxacin (both groups) and 600 mg rifampicin (Group MFX+RIF). MFX: moxifloxacin; RIF: rifampicin; AUC0-24h: 24-h area under the concentration-time curve; Cmax: peak observed concentration; Tmax: time when Cmax occurs; GMR: geometric mean ratio (Group MFX+RIF/MFX).
b
Geometric standard deviations.
c
Expressed in median and interquartile range instead of means and standard deviation.
d
Expressed in n (%) instead of means and includes all patients, n = 51.